Anti Radiation Drugs Market is expected to grow at a CAGR of 7.1% during the forecasted period | Evolve Business Intelligence

Key Highlights:
• The global Anti Radiation Drugs Market size was valued at USD 6.1 billion in 2023 growing at a CAGR of 7.1% from 2023 to 2033.
• North America dominated the market in 2023
• Asia Pacific is expected to grow at the highest CAGR from 2023 to 2033

As per the study initiated by Evolve Business Intelligence, the global Anti Radiation Drugs Market size accounted for USD 6.1 Billion in 2023, growing at a CAGR of 7.1% from 2023 to 2033. Anti-radiation drugs are a type of medication that can be used to reduce the harmful effects of radiation on the body. They work by either preventing radiation from being absorbed by the body or by helping to repair damage caused by radiation. The most common type of anti-radiation drug is potassium iodide (KI). KI is a non-radioactive form of iodine that can help to block the uptake of radioactive iodine by the thyroid gland. This is important because radioactive iodine can damage the thyroid gland and increase the risk of thyroid cancer.

Request/Download PDF Sample: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=021521

The primary use of radiation therapy in cancer treatment can cause damage to surrounding healthy tissues. Radioprotectors are explored to reduce these side effects and improve the overall safety and efficacy of cancer treatment. In the event of a nuclear accident, such as a reactor meltdown, there is interest in developing drugs or treatments that can mitigate the effects of radiation exposure on affected individuals. Concerns about potential radiation terrorism or intentional nuclear events have led to research into medical countermeasures that could be deployed in the aftermath of such incidents.

Key Players
Some of the major Anti Radiation Drugs Market players holding high market shares include Amgen Inc., Partner Therapeutics Inc., RedHill Biopharma Ltd., Humanetics Corporation, and RxBio Inc. These players use partnership and collaboration as a key strategy to gain significant market share to compete with market leaders. Some of the other major market players include Soligenix Inc., Aeolus Pharmaceuticals, Onconova Therapeutics, Genome Protection Inc., and others.

For More Information: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=021521

Segmental Analysis
Based on indication, the Anti Radiation Drugs market is segmented into Acute Radiation Syndrome and Delayed Radiation Syndrome. The Acute Radiation Syndrome (ARS) segment is the largest segment of the Anti Radiation Drugs market. ARS is a serious and potentially fatal condition that can occur after exposure to high levels of ionizing radiation. The severity of ARS depends on the amount of radiation exposure and the individual's age, health, and genetics. There is no cure for ARS, but there are treatments that can help to mitigate the symptoms and improve the chances of survival.
Based on the route of administration, the Anti Radiation Drugs market is Oral and Intramuscular. The oral route of administration is the largest segment of the Anti Radiation Drugs market. Oral drugs are generally easier to administer and more convenient for patients to take than injectable drugs. They are also less likely to cause side effects such as pain and infection.
Based on distribution channels, the Anti Radiation Drugs market is Hospital Pharmacies, Retail Pharmacies, and others. Hospital pharmacies are the largest distribution channel for anti-radiation drugs. This is because hospital pharmacies have access to a wide range of anti-radiation drugs and can provide patients with the necessary information and support to take these drugs safely and effectively.

Key Region/ Countries Covered
• North America (US, Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Spain, Russia, Nordic Countries, BeNeLux, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Rest of Asia Pacific)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa, Rest of MEA)
• Latin America (Mexico, Brazil, Argentina, Rest of Latin America)

Address
Evolve Business Intelligence
C-218, 2nd floor, M-Cube
Gujarat 396191
India
Email: sales@evolvebi.com
Website: https://evolvebi.com/

About EvolveBI
Evolve Business Intelligence is a market research, business intelligence, and advisory firm providing innovative solutions to challenging pain points of a business. Our market research reports include data useful to micro, small, medium, and large-scale enterprises. We provide solutions ranging from mere data collection to business advisory.
Evolve Business Intelligence is built on account of technology advancement providing highly accurate data through our in-house AI-modelled data analysis and forecast tool - EvolveBI. This tool tracks real-time data including, quarter performance, annual performance, and recent developments from Fortune's global 2000 companies.

This release was published on openPR.